Neumora Therapeutics Initiates Phase 1 Clinical Study of NMRA-898
Neumora Therapeutics, Inc. announced the initiation of a Phase 1 single-ascending dose/multiple-ascending dose (SAD/MAD) study of NMRA-898, a structurally distinct M4 Positive Allosteric Modulator.
NMRA-898 is the second M4 PAM in Neumora's M4 franchise, with both programs showing potential best-in-class pharmacology. Pre-clinical studies conducted in multiple species, including rabbits, did not observe convulsions.
Neumora plans to provide a comprehensive M4 franchise update by mid-2026.
No convulsions observed in pre-clinical studies conducted in multiple species, including rabbits.
Author's summary: Neumora starts Phase 1 study of NMRA-898.
More News
- How many syllables in breezes?
- Macclesfield see off Slough in extra-time
- GROUND | traduire en français - Cambridge Dictionary
- Suryakumar Yadav Breaks Past Rohit Sharma to Set New Mumbai T20 Batting Record
- Evidence of burial ground at Tuam mother and baby home
- The journey continues: Courtois shines at San Mamés
- BREEZE Instagram Bio Summary
- FGR manager Robbie Savage focus of new BBC documentary
- Ground verb - meaning and usage
- Skippylongstocking excels in Harlan’s Holiday Stakes